Results 101 to 110 of about 27,000 (252)

GMP‐compliant production, validation and dosimetry of clinical grade [18F]3‐(3‐fluoropropyl)‐2‐phenyl‐2,3‐dihydrobenzo[d]thiazole ([18F]FPBT) for oxidative stress PET imaging

British Journal of Pharmacology, EarlyView.
Background and Purpose Oxidative stress plays a critical role in the pathophysiology of various diseases, yet current methods for its non‐invasive detection remain limited. This study aimed to systematically validate a superoxide‐selective PET tracer, [18F]FPBT, for the early diagnosis and therapeutic monitoring of oxidative stress‐related conditions ...
Hua Zhang, Fangfang Sun, Chun Li, Xin Wang, Yuexuan Song, Lu Jiang, Paul Gape, Samantha Y. A. Terry, Shujun He, Ran Yan, Zhi Lu   +10 more
wiley   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

Survival After Diagnosis of Cardiovascular Disease in Survivors of Adolescent and Young Adult Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Cardiac dysfunction is a major morbidity among survivors of adolescent and young adult (AYA) lymphoma. Although high mortality after cardiovascular disease (CVD) diagnosis has been shown in other cancer survivor populations, this has not been investigated in a diverse population of survivors of AYA lymphoma.
Karan Gowda, Medha Gupta, Adrian Aguilar, Carlos Cruz, Amanda Warner, Elizabeth R. Rodriguez, Sairah Ahmed, Branko Cuglievan, Joel Milam, David R. Freyer, Kimberly A. Miller, Greg Aune, Debra Eshelman‐Kent, Karen Albritton, Efstratios Koutroumpakis, Michael E. Roth, Jian Wang, Michelle A. T. Hildebrandt   +17 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Feasibility and Safety of Venetoclax for Cytoreduction During Induction Therapy in Newly Diagnosed Acute Promyelocytic Leukemia

European Journal of Haematology, EarlyView.
ABSTRACT Objective This study aimed to evaluate the feasibility and safety of venetoclax as a cytoreductive strategy during induction therapy in newly diagnosed acute promyelocytic leukemia (APL), and to provide an exploratory description of its early efficacy.
Yu Wang, Rong Xiao, Xiaobing Huang, Yi Xiao   +3 more
wiley   +1 more source

KRAS Mutations Predict Inferior Post‐Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations

European Journal of Haematology, EarlyView.
ABSTRACT Somatic mutations in the MAPK signaling pathway are frequently identified at AML diagnosis; however, their impact on treatment resistance and long‐term survival remains unclear. We conducted a retrospective study of patients with newly diagnosed MAPK‐mutated AML seen at the University of Iowa Health Care.
Kensuke Takaoka, Sarah Mott, Ratdanai Yodsuwan, Sakditad Saowapa, Manasawee Tanariyakul, Chalothorn Wannaphut, Kittika Poonsombudlert   +6 more
wiley   +1 more source

A new branch of mammalian vitamin B6 metabolism: AKR1C‐mediated conversion of pyridoxal to pyridoxine and 4‐pyridoxolactone

The FEBS Journal, EarlyView.
Pyridoxal 5′‐phosphate (PLP) homeostasis relies on salvage enzymes, yet key metabolic branches remain undefined. We identify AKR1C isozymes as previously undescribed contributors that convert pyridoxal into pyridoxine or 4‐pyridoxolactone through reductase and dehydrogenase activities.
Nayu Kito, Yasuyuki Kitaura, Kyoka Iino, Kazuya Toriumi, Hyunah Noh, Naoya Ogawa, Makoto Arai, Hisashi Hemmi, Tomokazu Ito   +8 more
wiley   +1 more source

Anthracycline-induced cardiorenal toxicity: from molecular mechanisms to clinical management. [PDF]

Front Cardiovasc Med
Jiao L, Yuan C, Wang L, Zhao Y, Zhang G, Yang X, Gao Y, Yang F, Li X, An N, Shang H, Xing Y.   +11 more
europepmc   +1 more source

Outcomes of Kaposi sarcoma in people living with HIV who maintain long‐term viral suppression: A prospective case‐series

HIV Medicine, EarlyView.
Abstract Background Data on chemotherapeutic efficacy and tolerability for Kaposi Sarcomas (KS) in people living with HIV (PWH) and HIV‐virological control are limited. We aimed to describe clinical responses and tolerability of KS therapies in PWH with HIV‐aviraemic KS in a prospective cohort.
S. Bacquart, R. Palich, M. Veyri, S. Bregigeon‐Ronot, M.‐C. Picot, C. Vidal, L. Galicier, S. Choquet, J.‐P. Spano, M.‐A. Valantin, A. Makinson   +10 more
wiley   +1 more source